News und Analysen
![Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
![Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca® (rucaparib) in multiple tumor types have
![Agilent Reports Second-Quarter Fiscal Year 2020 Financial Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Agilent Reports Second-Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.24 billion for the second quarter ended April 30, 2020, equal to revenue reported for the second quarter of 2019 and down 1.7% on a
![Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief
![Top Pharmaceutical Company Visionaries to Keynote Veeva Summit Online](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Top Pharmaceutical Company Visionaries to Keynote Veeva Summit Online
Veeva Systems (NYSE: VEEV) today announced that Barry Greene, president at Alnylam Pharmaceuticals, and Andy Schmeltz, global president and general manager of oncology at Pfizer Inc., will be
![IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive
![Sensorion Publishes Results of General Assembly Resolutions](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Sensorion Publishes Results of General Assembly Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
![Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of
![Agilent Announces Cash Dividend of 18 Cents Per Share](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Agilent Announces Cash Dividend of 18 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on July 22, 2020, to all shareholders of record as of the close of
![NanoString and OnRamp BioInformatics Partner to Develop Cloud-Based Analysis Solutions for nCounter Data](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
NanoString and OnRamp BioInformatics Partner to Develop Cloud-Based Analysis Solutions for nCounter Data
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis
![New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders1 that showed
![Humana and Healthmap Solutions Sign Agreement for Kidney Disease Care Coordination Services in Florida](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana and Healthmap Solutions Sign Agreement for Kidney Disease Care Coordination Services in Florida
Leading health and well-being company Humana Inc. (NYSE: HUM) and Healthmap Solutions, Inc., a specialty population health management company with kidney health expertise, today announced a
![MEDICREA Reports 2020 First Quarter Results](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
MEDICREA Reports 2020 First Quarter Results
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling
![NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020
Paris and Boston, May 19th, 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in
![Premier Inc. Launches New Program to Invest in Domestic and Diverse Manufacturing Capabilities](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Premier Inc. Launches New Program to Invest in Domestic and Diverse Manufacturing Capabilities
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced a new program to invest in domestic and geographically diverse manufacturers to ensure a robust and resilient
![LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement
![Veeva Enables CROs to Build Studies Faster with Vault EDC](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Veeva Enables CROs to Build Studies Faster with Vault EDC
Veeva Systems (NYSE:VEEV) today announced a new partner program to help CROs build studies faster using Veeva Vault EDC. As part of the CRO partner program, CROs are trained and receive best
![Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials
Veeva Systems (NYSE: VEEV) today announced Veeva Vault Site Connect, a new application that connects sponsors and clinical research sites during trials. Vault Site Connect automates the flow of
![Veeva Announces MyVeeva to Enable Patient-Centric Clinical Trials](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Veeva Announces MyVeeva to Enable Patient-Centric Clinical Trials
Veeva Systems (NYSE: VEEV) today announced MyVeeva, a new application for clinical research sites. With capabilities for virtual visits, patient adherence, ePRO, eConsent, eSource and an easy to
![Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabozantinib) versus Stivarga® (regorafenib) for
![Gilead, Evotec und CytoDyn – 3 dringende Verkaufskandidaten!](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Gilead, Evotec und CytoDyn – 3 dringende Verkaufskandidaten!
Gilead Sciences (WKN: 885823), CytoDyn (WKN: A0YHA5) und Evotec (WKN: 566480) – die Aktien der drei Pharmaunternehmen sind in diesem Jahr – trotz oder gerade wegen Corona – vergleichsweise gut
![Pfizer Prices $4,000,000,000 Debt Offering](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Pfizer Prices $4,000,000,000 Debt Offering
Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of four tranches of notes:
$750,000,000 aggregate principal amount of 0.800% notes due 2025
$1,000,000,000
![Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Clovis Oncology Announces Pricing of Public Offering of Common Stock](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Clovis Oncology Announces Pricing of Public Offering of Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before
![Clovis Oncology Announces Proposed Offering of Common Stock](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Clovis Oncology Announces Proposed Offering of Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.
Clovis Oncology intends to offer, subject to market and other